Clinical Trial Results:
Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM8101) to improve proGNosis and outcomES in covid-19 Trial
Summary
|
|
EudraCT number |
2020-001336-10 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Jun 2025
|
First version publication date |
12 Jun 2025
|
Other versions |
|
Summary report(s) |
Synopsis clinical study report |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.